GENETIC FACTORS INFLUENCING THE EFFECTIVENESS AND SAFETY OF LONG-TERM ANTICOAGULANT THERAPY
https://doi.org/10.15829/1728-8800-2013-3-89-94
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Late postoperative thrombotic and haemorrhagic complications in anticoagulant-treated patients remain one of the key problems of the modern clinical medicine. At present, the most widely used anticoagulant is warfarin, a vitamin K antagonist. One of the reasons for a pathological reaction to the therapeutic concentration of warfarin could be individual features of warfarin metabolism, determined by relevant genes. The literature data suggest that protein-coding CYP2C9 and VKORC1 genes play an important role in the development of postoperative complications. However, the individual warfarin dosage can be influenced by a wide range of other genetic polymorphisms.
About the Authors
T. V. Burkova
Research Institute of Complex Cardiovascular Problems, Siberian Branch, Russian Academy of Medical Sciences, Kemerovo
Russian Federation
tel.: (3842) 64–46–50
Russian Federation
tel.: (3842) 64–46–50
I. A. Goncharova
Research Institute of Complex Cardiovascular Problems, Siberian Branch, Russian Academy of Medical Sciences, Kemerovo
Russian Federation
Russian Federation
References
1. Andreeva EN, Jarovaja IS, Uzhegova ZhA. Experience of using regulon - Low-dose estrogen-progestin drug in normogonadotropnoy amenorrhea in adolescent girls. Russian Journal of obstetrician 2004; 4, 3: 48-50. Russian (Andreeva E. N., Yarovaya I. S., Uzhegova Zh. A. Opyt primeneniya regulona - nizkodozirovannogo estrogen-gestagennogo preparata pri normogonadotropnoi amenoree u devushek-podrostkov. Rossiiskii vestnik akushera-ginekologa 2004; 4, 3: 48-50).
2. Baranov VS. Genetic passport - the basis of individual and predictive medicine. Spb.: Publishing House of the H-L. 2009: 528 pages. Russian (Baranov V. S. Geneticheskii pasport - osnova individual'noi i prediktivnoi meditsiny. Spb.: Izd-vo N-L 2009; 528 s).
3. Giljarov MJu, Generozov JeV, Magomadova MU, et al. Factors affecting the dose of warfarin in patients with atrial fibrillation. Cardiology 2008; 5: 65-8. Russian (Gilyarov M. Yu., Generozov E. V., Magomadova M. U. i dr. Faktory, vliyayushchie na dozirovku varfarina u patsientov s fibrillyatsiei predserdii. Kardiologiya 2008; 5: 65-8).
4. Grigor’eva NJu, Radzinskij VE, Sokolova SL, et al. The role of the PLA GPIIIa gene polymorphism in the development of uterine fibroids, adenomyosis, and combinations thereof. Herald PFUR 2002, 1: 17-25. Russian (Grigor'eva N. Yu., Radzinskii V. E.., Sokolova S. L. i dr. Rol' PLA polimorfizma gena GPIIIa v razvitii miomy matki, adenomioza i ikh sochetaniya. Vestnik RUDN 2002; 1: 17-25).
5. Zagorskaja VL, Kukes VG, Bajdak DV. Genetic aspects of antikoagulyaita warfarin in patients with cardiovascular disease. Proceedings of the XI International Symposium on “New Technologies in Rehabilitation Medicine and Health Resort» 2006: 40-1. Russian (Zagorskaya V. L., Kukes V. G., Baidak D. V. Geneticheskie aspekty primeneniya antikoagulyaita varfarina u bol'nykh s serdechnososudistoi patologiei. Materialy XI Mezhdunarodnogo simpoziuma «Novye tekhnologii vosstanovitel'noi meditsiny i kurortologii» 2006: 40-1).
6. Kukes VG. Drug Metabolism: clinical and pharmacological aspects. M: Reafarm 2004: 18-27, 40-7. Russian (Kukes V. G. Metabolizm lekarst- vennykh sredstv: kliniko-farmakologicheskie aspekty. M: Reafarm 2004: 18-27, 40-7).
7. Miheeva JuA, Kropacheva ES, Ignat’ev IV, et al. Ignat’ev I.V. et al. Polymorphism of cytochrome R4502S9 (CYP2C9) and safety of warfarin therapy. Cardiology 2008, 3: 77-83. Russian (Mikheeva Yu. A., Kropacheva E. S., Ignat'ev I. V. i dr. Ignat'ev I. V. i dr. Polimorfizm gena tsitokhroma R4502S9 (CYP2C9) i bezopasnost' terapii varfarinom. Kardiologiya 2008; 3: 77-83).
8. Panchenko EP, Miheeva JuA, Sychev DA, et al. A new approach to improving the safety of treatment with warfarin (pharmacogenetic research results). Heart J 2008; 2, 3: 38-44. Russian (Panchenko E. P., Mikheeva Yu. A., Sychev D. A. i dr. Novyi podkhod k povysheniyu bezopasnosti lecheniya varfarinom (rezul'taty farmakogeneticheskogo issledovaniya). Kardiologicheskii vestnik 2008; 2, 3: 38-44).
9. Radzinskij VE, Itkes AV, Ordijanc IM, et al. Genetic determinants of hyperplastic diseases of the reproductive system. Journal of Obstetrics and Female Diseases 2002, 3: 25-7. Russian (Radzinskii V. E., Itkes A. V., Ordiyants I. M. i dr. Geneticheskie determinanty giperplasticheskikh zabolevanii reproduktivnoi sistemy. Zhurnal akusherstva i zhenskikh boleznei 2002; 3: 25-7).
10. Rychkov AJu. Antikoaguljanty pri fibrilljacii predserdij. Anticoagulation in atrial fibrillation. Herald arrhythmology 2008, 50: 46-9. Russian (Rychkov A. Yu. Antikoagulyanty pri fibrillyatsii predserdii. Vestnik aritmologii 2008; 50: 46-9).
11. Sirotkina OV, Ulitina AS, Taraskina AE, et al. Allelic variants of the CYP2C9*2 and CYP2C9*3 gene cytochrome CYP2C9 in the population of St. Petersburg and their clinical significance in anticoagulation therapy with warfarin. Ros cardiology J 2004; 6: 24-31. Russian (Sirotkina O. V., Ulitina A. S., Taraskina A. E. i dr. Allel'nye varianty CYP2C9*2 i CYP2C9*3 gena tsitokhroma CYP2C9 v populyatsii Sankt-Peterburga i ikh klinicheskoe znachenie pri antikoagulyantnoi terapii varfarinom. RKZh 2004; 6: 24-31).
12. Stasjak EV, Sychev DA, Ignat’ev IV, et al. The frequency of the polymorphic allele CYP2C9*3 patients with permanent atrial fibrillation, which showed chronic administration of indirect anticoagulants. International Conference ”Clinical trials of drugs”, 4th: Materials. M. 2004: 245- 6. Russian (Stasyak E. V., Sychev D. A., Ignat'ev I. V. i dr. Chastota polimorfnogo allelya CYP2C9*3 u bol'nykh s postoyannoi formoi mertsatel'noi aritmii, kotorym pokazan postoyannyi priem nepryamykh antikoagulyantov. Mezhdunarodnaya konferentsiya «Klinicheskie issledovaniya lekarstvennykh sredstv», 4-ya: Materialy. M. 2004: 245-6).
13. Sychev DA, Antonov IM, Zagrebin SV, et al. Warfarin dosing algorithms, based on the results of pharmacogenetic testing: a real opportunity to optimize pharmacotherapy. Rational Pharmacotherapy in Cardiology 2007, 2: 59-66. Russian (Sychev D. A., Antonov I. M., Zagrebin S. V., N.A. i dr. Algoritmy dozirovaniya varfarina, osnovannye na rezul'tatakh farmakogeneticheskogo testirovaniya: real'naya vozmozhnost' optimizatsii farmakoterapii. RFK 2007; 2: 59-66).
14. Sychev DA, Antonov IM, Kropacheva ES, et al. Which of warfarin dosing algorithms based on the results of pharmacogenetic testing, suitable Russian patients. Cardiology 2010; 50 (4): 35-8. Russian (Sychev D. A., Antonov I. M., Kropacheva E. S. i dr. Kakoi iz algoritmov dozirovaniya varfarina, osnovannykh na rezul'tatakh farmakogeneticheskogo testirovaniya, podkhodit rossiiskim patsientam. Kardiologiya 2010; 50 (4): 35-8).
15. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotypeguided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-70.
16. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133: 160-98.
17. Bezemer ID, Bare LA, Doggen JM, et al. Gene Variants Associated With Deep Vein Thrombosis. JAMA 2008; 299: 1306-14.
18. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111 (8); 4106-12.
19. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C Proc Natl Acad Sci USA 2006; 90: 1004-8.
20. Dumas TE, Hawke RL, Lee CR. Warfarin Dosing and the Promise of Pharmacogenomics. Current Clinical Pharmacology 2007; 2: 11-21.
21. Foti RS, Dickmann LJ, Davis JA, et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 2008; 38 (3): 264-80.
22. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001; 109: 369-84.
23. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84: 326-31.
24. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism A meta-analysis involving ~120,000 cases and 180,000 controls. Thromb Haemost 2009; 102: 360-70.
25. Guidelines on the management of valvular heart disease. The task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 2007; 2: 230-68.
26. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287 (13): 1690-8.
27. Jacquelin B, Tarantino M, Kritzik M, et al. Alleledependent transcriptional regulation of the human integrin α2 gene. Blood 2001; 97: 1721-6.
28. King CR, Deych E, Milligan P, et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010; 104 (4): 750-4.
29. Knuimana MW, Folsomb AR, Chamblessc LE, et al. Wue Association of Hemostatic Variables with MRI-Detected Cerebral Abnormalities: The Atherosclerosis Risk in Communities Study Neuroepidemiology. JAMA 2001; 20: 96-104.
30. McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant. Received January 2009; 75 (6): 1337-46.
31. Pellitero S, Reverter JL, Tassies D, et al. Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes. Thromb Haemost 2010; 103: 630-7.
32. Rieder MG. Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. N Engl J Med 2005; 352: 2285-93.
33. Rieder MG, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. Thromb Haemost 2007; 5 (11): 2227-34.
34. Salem DN, O’Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 593-629.
35. Shanker J, Perumal G, Maitra A, et al. Genotype-phenotype relationship of F7 R353Q polymorphism and plasma factor VII coagulant activity in Asian Indian families predisposed to coronary artery disease. J Genet 2009; 88: 291-7.
36. Stec DE, Roman RJ, Flasch A, et al. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics. Physiol Genomics 2007; 30: 74-81.
37. Trifonova E, Spiridonova M, Stepanov V. Genetic diversity and structure of linkeage disequilibrium in the MTHFR locus. European Human Genetic Conference May 31 - June 3, Barcelona. Spain. Eur J Hum Genet 2008; 16 (2): 323.
38. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a metaanalysis. Blood Coagulation & Fibrinolysis 2007; 18: 497-504.
39. Van Booven D, Marsh S, McLeod H, et al. P450 2C9-CYP2C9. Pharmacogenet Genomics 2010; 20 (4): 277-81.
40. Wysowski DK, Parivash Nourjah, Swartz L. Bleeding Complications With Warfarin Use A Prevalent Adverse Effect Resulting in Regulatory Action. MEd, MBA (REPRINTED) ARCH INTERN MED 2007; 167, 13: 1414-9.
Review
For citations:
Burkova T.V., Goncharova I.A. GENETIC FACTORS INFLUENCING THE EFFECTIVENESS AND SAFETY OF LONG-TERM ANTICOAGULANT THERAPY. Cardiovascular Therapy and Prevention. 2013;12(3):89-94. (In Russ.) https://doi.org/10.15829/1728-8800-2013-3-89-94
Views:
663
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Email this article 
